QUILTY EDWARD J Form SC 13D/A May 15, 2003

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934 (Amendment No. 7)*

Derma Sciences, Inc.

(Name of Issuer)

Common Stock, \$0.01 par value

(Title of Class of Securities)

249827205

(CUSIP Number)

Raymond C. Hedger
Hedger & Hedger

2 Fox Chase Drive, P.O. Box 915, Hershey, PA 17033
(717)534-9993

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

April 30, 2003

(Date of Event which Requires Filing of this Statement)

If the filing person has previously filed a statement of Schedule 13G to report the acquisition which is the subject of the Schedule 13D, and is filing this schedule because of ss. 240.13d-1(e), ss. 240.13d-1(f) or ss. 240.13d-1(g), check the following box [].

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See ss. 240.13d-7(b) for other parties to whom copies are to be sent.

*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

(Continued on following page(s))

PAGE 2

CUSIP No. 249827205		Schedule	13	D
1 NAME OF REPORTING PERSONS. OR I.R.S. IDENTIFY	SON FICATION NO. OF ABOVE PERSON			
Edward J. Quilty	101-42-3117			
2 CHECK THE APPROPRIATE	BOX IF A MEMBER OF A GROUP*	(a) (b)	 [[
3 SEC USE ONLY				_
4 SOURCE OF FUNDS*				-
5 CHECK BOX IF DISCLOSUL ITEMS 2(d) OR 2(e)	RE OF LEGAL PROCEEDINGS IS REQUIRED PURSU		[]
6 CITIZENSHIP OR PLACE (OF ORGANIZATION			-
United States				
NUMBER OF SHARES	7 SOLE VOTING POWER			
BENEFICALLY	775,990			
OWNED BY EACH	8 SHARED VOTING POWER			
REPORTING				
PERSON WITH	9 SOLE DISPOSITIVE POWER			-
	775,990			
	10 SHARED DISPOSITIVE POWER			_
	NEFICIALLY OWNED BY EACH REPORTING PERSON			-
775,990				-
12 CHECK BOX IF THE AGO	GREGATE AMOUNT IN ROW (11) EXCLUDES CERTA:			
			[_
	PRESENTED BY AMOUNT IN ROW (11)			
15.21% 				. –
14 TYPE OF REPORTING P	ERSON*			
IN				-
*SEE	INSTRUCTIONS BEFORE FILLING OUT!			

PAGE 3

CUSIP No. 249827205 Schedule 13D

ITEM 1. SECURITY AND ISSUER

This Schedule 13D relates to the common stock, \$.01 par value (the "Common Stock"), of Derma Sciences, Inc., a Pennsylvania corporation (the "Issuer"), whose principal executive offices are located at 214 Carnegie Center, Suite 100, Princeton, New Jersey 08540.

ITEM 2. IDENTITY AND BACKGROUND

This Schedule 13D is being filed by Edward J. Quilty (the "Reporting Person"). Certain information with respect to the Reporting Person is set forth below:

Name and Address: Edward J. Quilty

214 Carnegie Center

Suite 100

Princeton, NJ 08540

Principal Occupation: Chairman of the Board of Directors, President

and Chief Executive Officer of the Issuer

Criminal convictions: None

Civil proceedings: None

Citizenship: United States

ITEM 3. SOURCE AND AMOUNT OF FUNDS OR OTHER CONSIDERATION

The options to purchase the common stock of the Issuer described under Item 5 were granted to the Reporting Person without payment of consideration.

The source and amount of funds used to effect the purchase of the Issuer's common stock described under Item 5 were personal funds of the Reporting Person in the amount of \$5,000.

ITEM 4. PURPOSES OF THE TRANSACTIONS

The purpose of the reported, and all previous, acquisitions of the Issuer's Common Stock, together with options to purchase same, is investment without a view, presently or ultimately, to acquiring control of the Issuer. The Reporting Person serves as Chairman of the Board of Directors, President and Chief Executive Officer of the Issuer. In this capacity, the Reporting Person has proposed, and may in the future propose, candidates for election to the Issuer's board of directors.

There is no agreement or arrangement between the Reporting Person and the Issuer with respect to election of candidates proposed by the Reporting Person. The inclusion of such candidates in management's slate of directors to be submitted for consideration by the Issuer's shareholders is entirely at the discretion of the Issuer's board of directors.

PAGE 4

CUSIP No. 249827205

Schedule 13D

ITEM 5. INTEREST IN SECURITIES OF THE ISSUER

The following table sets forth shares of the Issuer's Common Stock as to which the Reporting Person maintains beneficial ownership. The Reporting Person maintains both voting power and dispositive power relative to all such shares:

Beneficial Common Stock Ownership

Owned outright Exercisable options (1) Exercisable options (2) Exercisable options (3) Exercisable options (4) Exercisable options (5) Exercisable warrants (6) Exercisable warrants (7)	311,684 20,000 40,000 76,055 90,000 12,000 6,250 220,001
Total beneficially owned	775 , 990
Percentage of class beneficially owned	15.21%
Evergiaphle at \$4.00 per abare	

(1)	Exercisable	a +	\$1 00	nar	chara

⁽²⁾ Exercisable at \$5.63 per share.

On March 25, 2003 the board of directors of the Issuer awarded to the Reporting Person "non-statutory" options to purchase 100,000 shares of the Issuer's common stock. The options are exercisable at the price of \$0.37 per share which price represents the closing price of the common stock on OTC Bulletin Board on the date of grant. The options are, or become, exercisable with respect to the following number of shares on the following dates: 6,225 on March 25, 2003, 6,250 on March 25, 2004, 6,250 on March 25, 2005, 6,250 on March 25, 2006 and 75,000 in accordance with the Reporting Person's attainment of performance objectives.

On April 30, 2003 the Reporting Person purchased from the Issuer 10,000 shares of the Issuer's common stock, \$0.01 par value, at a per share price of \$0.50 for a total investment of \$5,000. Previously, the Reporting Person had purchased in the same offering 50,000 shares of the Issuer's common stock at a per share price of \$0.50 for a total price \$25,000. To date, the Reporting Person and approximately 20 other institutional and individual investors purchased 3,270,000 shares of the Issuer's common stock, in the same offering and upon identical terms, for a total investment of \$1,635,000. The foregoing sales and purchases were effected in transactions not involving a public offering.

PAGE 5

CUSIP No. 249827205

Schedule 13D

ITEM 6. CONTRACTS, ARRANGEMENTS, UNDERSTANDINGS OR RELATIONSHIPS WITH RESPECT TO


⁽²⁾ Exercisable at \$5.05 per share.

⁽³⁾ Exercisable at \$5.93 per share.(4) Exercisable at \$0.40 per share.

⁽⁵⁾ Exercisable at \$0.61 per share.

⁽⁶⁾ Exercisable at \$0.37 per share.

⁽⁷⁾ Exercisable at \$0.85 per share.



None.

ITEM 7. MATERIAL TO BE FILED AS EXHIBITS

None.

SIGNATURES

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

/s/ Edward J. Quilty
----By: Raymond C. Hedger, Jr.
Attorney-in-Fact

May 7, 2003

POWER OF ATTORNEY: incorporated by reference to Edward J. Quilty's Schedule 13D/A, Amendment No. 4, filed on September 11, 2000.